<scp>VCE</scp>‐004.3, a cannabidiol aminoquinone derivative, prevents bleomycin‐induced skin fibrosis and inflammation through PPARγ‐ and CB₂ receptor‐dependent pathways

Abstract

VCE-004.3 is a novel semisynthetic cannabidiol derivative that behaves as a dual PPARγ/CB₂ agonist and CB₁ receptor modulator that could be considered for the development of novel therapies against different forms of scleroderma.